Curis/$CRIS
1D1W1MYTD1Y5YMAX
About Curis
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.
- Ticker
- $CRIS
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 22
- Headquarters
- Lexington, United States
- Website
- www.curis.com
Curis Metrics
BasicAdvanced
$3.1M
-
-$18.06
3.09
-
Price and volume
Market cap
$3.1M
Beta
3.09
52-week high
$6.74
52-week low
$1.40
Average daily volume
255K
Financial strength
Current ratio
0.492
Quick ratio
0.371
Total debt to equity
22.236
Interest coverage (TTM)
-29.99%
Profitability
EBITDA (TTM)
-35.869
Gross margin (TTM)
-494.65%
Net profit margin (TTM)
-490.33%
Operating margin (TTM)
-833.40%
Revenue per employee (TTM)
$200,000
Management effectiveness
Return on assets (TTM)
-93.23%
Return on equity (TTM)
455.34%
Valuation
Price to revenue (TTM)
0.405
Price to book
0.62
Price to tangible book (TTM)
-0.68
Price to free cash flow (TTM)
-0.057
Free cash flow yield (TTM)
-1,752.54%
Free cash flow per share (TTM)
-26.109
Growth
Revenue change (TTM)
-62.17%
Earnings per share change (TTM)
-79.84%
3-year revenue growth (CAGR)
-24.95%
10-year revenue growth (CAGR)
-5.43%
3-year earnings per share growth (CAGR)
-55.20%
10-year earnings per share growth (CAGR)
-29.75%
Curis News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.